CA
NZ
UK
AU
IND
US
SS Innovations International, Inc. (NASDAQ: SSII), a key player in medical specialties, reported a notable surge in revenue for the second quarter of 2026, boosting figures by 39.4% to $13.9 million. This increase comes on the heels of a steady rise in demand for …
Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a notable player in the pharmaceuticals sector with a marketCapitalizationof approximately $837 million, has taken a decisive step to enhance shareholder value by executing a $50 million accelerated share repurchase agreement with Jefferies LLC. This announcement follows the company’s …
Fate Therapeutics, Inc. (NASDAQ: FATE), a pioneering clinical-stage biopharmaceutical company focused on cellular immunotherapy, reported second-quarter revenue of $6.32 million, marking a 52.6% year-over-year decline. This drop reflects the ongoing challenges within the biotechnology sector as the company navigates through developmental hurdles, including regulatory …
LENSAR, Inc. (NASDAQ: LNSR) recorded a remarkable $16.5 million in revenue for the second quarter ended June 30, 2026, reflecting an 18% year-over-year growth from $13.9 million in the same quarter last year. This improvement underscores the increasing utilization of its ALLY Robotic Cataract …
MiNK Therapeutics, Inc. (NASDAQ: INKT) operates in the biotechnology sector, focusing on innovative treatments for cancer and immune disorders. The company reported a marketCapitalizationof about $56 million and $9.53 million in cash and equivalents. This financial position supports its efforts to develop its lead …
PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage biotechnology firm with a market capitalization of $41 million, reported a net loss of $9.8 million for the quarter ending June 30, 2026. This loss translates to $0.18 per share, a slight improvement compared to the $9.4 …
This reflects a significant increase from the $18.4 million loss reported during the same period last year. The financial results highlight ongoing operational challenges; however, the company secured $50 million through a successful private placement which bolsters its financial footing.
Sagimet Biosciences Inc. (NASDAQ: SGMT) operates in the pharmaceutical sector and is currently valued at a market capitalization of approximately $586 million. With $165.90 million in cash and equivalents on hand, the company is positioned to advance itsDrug Developmentinitiatives. Recent developments underscore investor interest, …
Biofrontera Inc. (NASDAQ: BFRI) is a biopharmaceutical firm specializing in dermatological treatments, boasting a market capitalization of approximately $16 million. For the quarter ending June 30, 2026, the company reported a remarkable net product revenue of $12 million, representing a significant increase of 32.9% …
CorMedix Inc. (NASDAQ: CRMD), a biotechnology company focused on therapeutic solutions, achieved consolidated revenue of $101.9 million for the second quarter of 2026, exemplifying a significant year-over-year increase from $39.7 million in the same period in 2025. The company's strong financial performance underscores its …
Please wait processing your request...